soul study semaglutide trial oral cardiovascular outcomes results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been soul trial oral semaglutide cardiovascular
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27


















